Literature DB >> 27604764

Impact of treatment on long-term visual function in retinal vein occlusion-response to the comment on: retinal vein occlusion and the use of a dexamethasone intravitreal implant (Ozurdex®) in its treatment.

Justus G Garweg1, Souska Zandi2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27604764     DOI： 10.1007/s00417-016-3459-y

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN： 0721-832X            Impact factor:   3.117


× No keyword cloud information.
  16 in total

1.  Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study.

Authors:  Jeffrey S Heier; W Lloyd Clark; David S Boyer; David M Brown; Robert Vitti; Alyson J Berliner; Husain Kazmi; Yu Ma; Brigitte Stemper; Oliver Zeitz; Rupert Sandbrink; Julia A Haller
Journal:  Ophthalmology       Date:  2014-03-27       Impact factor: 12.079

Review 2.  Best practices for treatment of retinal vein occlusion.

Authors:  Paul Hahn; Sharon Fekrat
Journal:  Curr Opin Ophthalmol       Date:  2012-05       Impact factor: 3.761

3.  Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion.

Authors:  Julia A Haller; Francesco Bandello; Rubens Belfort; Mark S Blumenkranz; Mark Gillies; Jeffrey Heier; Anat Loewenstein; Young-Hee Yoon; Marie-Louise Jacques; Jenny Jiao; Xiao-Yan Li; Scott M Whitcup
Journal:  Ophthalmology       Date:  2010-04-24       Impact factor: 12.079

4.  Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study.

Authors:  David M Brown; Jeffrey S Heier; W Lloyd Clark; David S Boyer; Robert Vitti; Alyson J Berliner; Oliver Zeitz; Rupert Sandbrink; Xiaoping Zhu; Julia A Haller
Journal:  Am J Ophthalmol       Date:  2012-12-04       Impact factor: 5.258

5.  Natural history of macular status in recent-onset branch retinal vein occlusion: an optical coherence tomography study.

Authors:  Daraius Shroff; Dinesh Kumar Mehta; Ritu Arora; Ritesh Narula; Deepender Chauhan
Journal:  Int Ophthalmol       Date:  2007-08-01       Impact factor: 2.031

6.  EVALUATION OF MULTIPLE DEXAMETHASONE INTRAVITREAL IMPLANTS IN PATIENTS WITH MACULAR EDEMA ASSOCIATED WITH RETINAL VEIN OCCLUSION.

Authors:  Sophie J Bakri; Ahmed F Omar; Raymond Iezzi; Kapil G Kapoor
Journal:  Retina       Date:  2016-03       Impact factor: 4.256

7.  Natural course of experimental retinal vein occlusion in rabbit; arterial occlusion following venous photothrombosis.

Authors:  Hossein Ameri; Tanapat Ratanapakorn; Narsing A Rao; Gerald J Chader; Mark S Humayun
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-07-19       Impact factor: 3.117

8.  Real-world assessment of intravitreal dexamethasone implant (0.7 mg) in patients with macular edema: the CHROME study.

Authors:  Wai-Ching Lam; David A Albiani; Pradeepa Yoganathan; John Chanchiang Chen; Amin Kherani; David Al Maberley; Alejandro Oliver; Theodore Rabinovitch; Thomas G Sheidow; Eric Tourville; Leah A Wittenberg; Chris Sigouin; Darryl C Baptiste
Journal:  Clin Ophthalmol       Date:  2015-07-10

Review 9.  Retinal vein occlusion and the use of a dexamethasone intravitreal implant (Ozurdex®) in its treatment.

Authors:  Justus G Garweg; Souska Zandi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-05-13       Impact factor: 3.117

10.  Two-year, prospective, multicenter study of the use of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in the clinical setting in France.

Authors:  Jean-François Korobelnik; Laurent Kodjikian; Cécile Delcourt; Vincent Gualino; Richard Leaback; Sybil Pinchinat; Marie-Eve Velard
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-06-11       Impact factor: 3.117
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.